Zenas BioPharma (ZBIO) EBITDA Margin (2023 - 2025)

Zenas BioPharma (ZBIO) recorded quarterly EBITDA Margin of 336.26% in Q1 2025, up 67.95% quarter-over-quarter from 1049.26% in Q4 2024.

Zenas BioPharma (ZBIO) EBITDA Margin (2023 - 2025) Analysis & Trends

Zenas BioPharma's EBITDA Margin history runs 3 years deep, the most recent figure standing at 336.26% for Q1 2025.

In Q1 2025, EBITDA Margin changed N/A year-over-year to 336.26%; the TTM figure through Dec 2025 stood at 3779.95% (down 64337.0% YoY), while the FY2025 annual figure was 3779.95%, down 64333.0% from the prior year.
EBITDA Margin was 336.26% for Q1 2025 at Zenas BioPharma, up from 1049.26% in the prior quarter.
In the past five years, EBITDA Margin ranged from a high of 71.23% in Q3 2023 to a low of 1049.26% in Q4 2024.
Historically, EBITDA Margin has averaged 438.1% across 3 years, with a median of 336.26% in 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBITDA Margin (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	-6.43%
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	38.10%
9	Abivax	91.96 Bn	91.96 Bn	-	-
10	Zenas BioPharma	1.10 Bn	379.43 Mn	-	-

Download Data